CD8A and neoplasm: It is suspected that such glycolysis inhibitors, by decreasing the amount of glucose that tumor cells take up, relatively alleviate the competitive pressure for glucose in tumor tissues, improving immune cells’ access to glucose, which may lead to an increase in the quantity and degree of activation of antitumor immune cells, such as CD8+ T cells.